[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski… - The lancet …, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - Lancet Oncol, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
[PDF][PDF] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - Lancet Oncol, 2012 - academia.edu
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - The Lancet …, 2012 - Elsevier
BACKGROUND: Many patients with advanced non-small-cell lung cancer (NSCLC) receive
only active supportive care because of poor performance status or presence of several …
only active supportive care because of poor performance status or presence of several …
[引用][C] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - The Lancet …, 2012 - cir.nii.ac.jp
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for
chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial | CiNii Research …
chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial | CiNii Research …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay, C Lewanski… - The Lancet …, 2012 - kclpure.kcl.ac.uk
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - The Lancet …, 2012 - infona.pl
Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active
supportive care because of poor performance status or presence of several comorbidities …
supportive care because of poor performance status or presence of several comorbidities …
[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …
SM Lee, I Khan, S Upadhyay, C Lewanski… - The Lancet …, 2012 - ncbi.nlm.nih.gov
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay… - The Lancet …, 2012 - research.birmingham.ac.uk
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for
chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial — University of …
chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial — University of …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
SM Lee, I Khan, S Upadhyay, C Lewanski… - The Lancet …, 2012 - europepmc.org
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …